Key facts
- Pulmotect’s last known valuation is $59.3M.
- It has raised $29.5M across 6 recorded rounds; the latest was Early Stage VC ($10.3M) in Aug 2024.
- Notable investors include United States Department of War, SkyWalker Property Partners, Jefferson River Capital, Axil Capital Partners, Baylor Angel Network — 13 tracked in total.
- Pulmotect has filed 12 Form Ds with the SEC since 2016, most recently Sep 2024 ($10.3M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Pulmotect
Funding rounds
6 roundsAbout Pulmotect
Developer of a respiratory therapeutics technology intended to reduce morbidity and mortality in patients at risk of severe respiratory diseases. The company's therapeutics technology stimulates the body's natural defenses to provide broad-spectrum, fast-acting protection against bacterial pneumonia, influenza, fungal pneumonia and Class A bioterror agents, enabling caregivers to prevent and treat respiratory infections.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2007
- Employees
- 10
- Website
- pulmotect.com/
- Ownership
- Privately Held (backing)
Pulmotect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pulmotect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pulmotect in its N-PORT filings yet. We sweep new filings monthly.